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Functional Improvement
After Ventricular
Assist Device Implantation
Is Ventricular Recovery More
Common Than We Thought?*
Eric Adler, MD, Jorge Silva Enciso, MD
San Diego, California
He who’s down one day can be up the next,
unless he really wants to stay in bed, that is . . .
—Miguel de Cervantes Saavedra, Don Quixote (1)
Of the roughly 5.8 million Americans with heart failure,
approximately 10% will have Stage D heart failure, defined
as symptoms at rest despite optimal medical therapy. Amer-
ican College of Cardiology/American Heart Association
and European Society of Cardiology guidelines recommend
3 options for these patients: 1) a ventricular assist device
(VAD); 2) a heart transplant; or 3) hospice care (2).
Unfortunately, advanced therapies such as transplant and
VAD are associated with significant morbidity and mortal-
ity. Patients with both therapies take numerous medicati-
ons and are at lifelong risk for life-threatening infection.
See page 1985
Patients with VAD are at risk for other complications as
well, including bleeding, stroke, and device failure. But,
given the limited pool of suitable cardiac donors and vast
improvements in technology, it is of no surprise that the use
of VAD has increased dramatically. Since the U.S. Food and
Drug Administration’s approval of the Heart Mate II
continuous-flow (CF) left ventricular assist device (LVAD)
(Thoratec Corp., Pleasanton, California), 10,000 of these
devices have been placed in the last 5 years. More surprisingly,
last year, more VAD implantations were performed than heart
transplants—the first time this has ever occurred (3).
The vast majority of VAD implantations are performed
with the intent that the patient will either die with the VAD
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disclose.(aka destination therapy) or have the VAD until they receive
a heart transplant (aka bridge to transplant [BTT]). VAD
also theoretically should allow for and/or assist in the
recovery of cardiac function (bridge to recovery [BTR]).
Ventricular recovery would obviously be the ideal therapeu-
tic outcome from a VAD. Animal models suggest that the
combination of mechanical unloading with normalization of
the neurohormonal milieu can result in significant reverse
remodeling, challenging the dogma that heart failure is a
progressive, incurable disease (4). But previous BTR trials
using the older generation, pulsatile devices, have had mixed
results. A single-center study of 39 consecutive patients with
pulsatile VAD found only 1 patient to be suitable for
explantation (5). The multicenter LVAD working group
studied 67 patients, mostly of nonischemic etiology and sup-
ported by pulsatile VAD. Thirty-four percent had ejection
fractions (EF) 40 within 30 days of implantation. Unfortu-
nately, by 120 days, the majority of these patients had their EF
decrease to their pre-VAD measurement and only 9% under-
went LVAD explantation for recovery. Of note, in a subgroup
of 20 BTT patients from the study, histologic analysis of the
heart was performed at the time of LVAD placement and
again at transplant. Unloaded hearts were found to have
reduced myocyte size, lowered total collagen deposition, and
decreased myocardial tumor necrosis factor–alpha content; all
of this suggests positive remodeling with LVAD (6).
Several smaller studies suggest that rates of BTR may
occur in up to 15% of patients. Pre-explantation EF as well
as change in LV size and geometry were the greatest
predictors of recovery (7,8). Unfortunately, the use of
adjuvant neurohormonal blockade was not standardized in
any of these trials. A more recent prospective study in 20
patients with LVAD tested the hypothesis that recovery
could be enhanced by combining LVAD unloading with an
aggressive pharmacologic regimen and use of the novel
beta-2 agonist clenbuterol. Sixty percent of patients were
successfully explanted, despite the fact that most patients
had an EF of 14% to 15% at baseline and higher end-
diastolic diameters than in the previous studies. Such results
have yet to be reproduced in a larger trial (9).
Outside of clinical trials, BTR is rarely observed.
According to the INTERMACS (Interagency Registry
for Mechanically Assisted Circulatory Support) of me-
chanical circulatory support, less than 5% of patients in
the United States have had their VAD explanted because
of recovery of function. These VAD explantations have
been generally limited to patients with acute processes in
young patients with shorter duration of heart failure such
as acute myocarditis, post-cardiotomy syndrome, and
peripartum cardiomyopathy.
In this issue of the Journal, Drakos et al. (10) suggest a
simple explanation for the lack of recovery noted in the
registries: We simply are not looking hard enough. This
single-center prospective study investigated the effects of
CF-VAD unloading on myocardial structure as well as
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findings. A total of 80 patients were enrolled with echocar-
diograms and right heart catheterizations done serially after
CF-VAD implantation. Recovery in cardiac function was
based on improvement of echocardiographic parameters
during weaning trials performed serially throughout the
year. At 6 months, over one-third of patients had a 50%
relative improvement in EF when compared with pre-
implantation levels of CF-VAD (from pre-CF-VAD
LVEF to highest post-CF-VAD LVEF). More surpris-
ingly, 19% of these patients maintained an EF greater than
40% after 6 months of mechanical unloading. The systolic
and diastolic parameters improved along with a decrease in
chamber volume size and mass. Unlike previous studies, this
study only includes CF-VAD patients as opposed to the
first-generation pulsatile VAD. Though CF-VAD have
been shown to improve morbidity and mortality in compar-
ison with pulsatile VAD, it is unclear which ones promote
recovery; this study suggests that CF-VAD are better.
Unlike previous studies, Drakos et al. (10) recorded serial
echocardiographic parameters over a full year. In fact,
patients did not achieve full “benefit” from their VAD until
6 months after implantation, which may be a possible
explanation for why these findings differ from earlier work.
Also, unlike other studies, the investigators excluded pa-
tients that had acute heart failure, so they did not skew the
data toward patients likely to have recovery.
The greatest improvement in the study was seen in
younger patients and those with shorter durations of heart
failure; this is consistent with previous studies. But, contrary
to other studies, a relatively high proportion of ischemic
patients demonstrated improvements in structure and func-
tion. Initially, this might seem counterintuitive, as one
would think that ischemic patients would have the most
scarring and least chance of recovery. One possible expla-
nation is that many of the ischemic patients have a hiber-
nating myocardium that recovers as coronary perfusion
pressures improve and metabolic demands decrease.
Continuous mechanical unloading promoted positive and
sustained remodeling over time as seen by echocardio-
graphic changes in chamber dimension, LV mass, and EF.
This was consistent with 2 previous studies (8,11). Such
structural changes can potentially select patients for VAD
removal (i.e., those with EF 40%); however, the number
of patients studied at long-term follow-up was low. Echo-
cardiographic data from the current study demonstrates that
LV mass decreases, but does not go below the reference
range. This implies that unloading does not lead to signif-
icant cardiac atrophy and is consistent with older studies
(12). Clearly, pathologic data from cardiac explants would
help to support this conclusion.
Though the findings are encouraging, many issues remain
unresolved. The intent of the work was not to explant
patients, and in fact no patients were explanted. The
question remains: Would these patients retain the improve-
ment in function once the VAD was removed?Even if these patients did not go on to explantation, does
the recovery in function ultimately translate into an im-
provement in destination therapy/BTT outcomes? Cur-
rently, BTT patients are automatically United Network for
Organ Sharing status 1 (1A or 1B) on the transplant list
indefinitely until they are transplanted. If mortality is
different for those with some LV recovery in comparison
with those with no recovery, it would be reasonable to
stratify them on the list. Longer-term outcome studies will
be needed to address this question.
Drug therapy was not standardized in the patients. In
fact, less than one-third of patients were on beta-blockers.
Whether standard heart failure therapies improve outcomes
for VAD patients remains unknown and merits further
study. Mechanical circulatory support may help optimize
other more novel therapeutics, such as cell-based therapies,
but combination studies using LVAD and cell therapy have
been limited.
LVAD speed settings among patients varied significantly
in the study. Thus, whether certain LVAD speeds promote
recovery is unknown. It has also been speculated that full
recovery of function will require gradual “weaning” of the
LVAD. Next-generation centrifugal devices that allow for
low speed settings for a prolonged period of time will be
necessary to test this hypothesis.
Mechanical circulatory support has had a profound impact
on the treatment of heart failure, but at a significant cost to an
already strained health-care system; the estimated cost is
$86,000 per quality-of-life year (13). Given the fixed costs
associated with implantation, pursuing strategies to improve
morbidity and mortality after implantation should be of high
priority. If the devices can reach their full potential as thera-
peutic tools to treat heart failure, it will be money well spent.
Reprint requests and correspondence: Dr. Eric David Adler,
Department of Cardiology, University of California–San Diego,
9500 Gilman Drive, 0613K, San Diego, California 92122. E-mail:
eradler@ucsd.edu.
REFERENCES
1. Don Quixote Miguel de Cervantes, translated and annotated by Edith
Grossman. Harper Perennial, 2005.
2. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update:
ACCF/AHA Guidelines for the Diagnosis and Management of Heart
Failure in Adults: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice
Guidelines. J Am Coll Cardiol 2009;53:1343–82.
3. Kirklin JK, Naftel DC, Kormos RL, et al. The Fourth INTERMACS
Annual Report: 4,000 implants and counting. J Heart Lung Trans-
plant 2012;31:117–26.
4. Burkhoff D, Klotz S, Mancini DM. LVAD-induced reverse remod-
eling: basic and clinical implications for myocardial recovery. J Card
Fail 2006;12:227–39.
5. Mancini DM, Beniaminovitz A, Levin H, et al. Low incidence of
myocardial recovery after left ventricular assist device implantation in
patients with chronic heart failure. Circulation 1998;98:2383–9.
6. Maybaum S, Mancini D, Xydas S, et al., for the LVAD Working
Group. Cardiac improvement during mechanical circulatory support: a
prospective multicenter study of the LVAD Working Group. Circu-
lation 2007;115:2497–505.
1997JACC Vol. 61, No. 19, 2013 Adler and Enciso
May 14, 2013:1995–7 Effects of LVAD Unloading on Cardiac Function7. Dandel M, Weng Y, Siniawski H, et al. Heart failure reversal by
ventricular unloading in patients with chronic cardiomyopathy: criteria for
weaning from ventricular assist devices. Eur Heart J 2011;32:1148–60.
8. Simon MA, Primack BA, Teuteberg J, et al. Left ventricular remod-
eling and myocardial recovery on mechanical circulatory support.
J Card Fail 2010;16:99–105.
9. Birks EJ, George RS, Hedger M, et al. Reversal of severe heart failure
with a continuous-flow left ventricular assist device and pharmacolog-
ical therapy: a prospective study. Circulation 2011;123:381–90.
10. Drakos SG, Wever-Pinzon O, Selzman CH, et al. Magnitude and
time course of changes induced by continuous-flow left ventricular
assist device unloading in chronic heart failure: insights into cardiac
recovery. J Am Coll Cardiol 2013;61:1985–94.11. Dandel M, Weng Y, Siniawski H, et al. Prediction of cardiac stability
after weaning from left ventricular assist devices in patients with idiopathic
dilated cardiomyopathy. Circulation 2008;118 Suppl 14:S94–105.
12. Drakos SG, Kfoury AG, Hammond EH, et al. Impact of mechanical
unloading on microvasculature and associated central remodeling features
of the failing human heart. J Am Coll Cardiol 2010;56:382–91.
13. Hutchinson J, Scott DA, Clegg AJ, et al. Cost-effectiveness of left
ventricular-assist devices in end-stage heart failure. Expert Rev Car-
diovasc Ther 2008;6:175–85.Key Words: cardiac recovery y left ventricular assist device y
mechanical unloading y myocardial function y myocardial structure.
